Who Paid My Doc
Mark Blecher
Ophthalmology Philadelphia, PA Medical Doctor
NPI 1356343248 CMS profile 197049
1703 S Broad St, Philadelphia, PA 19148
General payments
$357,306
Research payments
$0
Ownership & investment interest
$240
Through program year 2025, Mark Blecher of Philadelphia, PA is reported in the CMS Open Payments database as having received $357,306 across 220 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $240 across 3 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,473 | 23 | |
| 2024 | General | $16,998 | 16 | |
| 2023 | General | $34,417 | 16 | |
| 2022 | General | $36,824 | 29 | |
| 2021 | General | $57,304 | 26 | |
| 2020 | General | $69,455 | 34 | |
| 2019 | General | $133,835 | 76 | |
| 2021 | Ownership | $84 | 1 | |
| 2020 | Ownership | $84 | 1 | |
| 2019 | Ownership | $72 | 1 |
Beside peers
- Mark Blecher
- Ophthalmology median
- Middle half of Ophthalmology
- National median
In program year 2025, general payments to Mark Blecher were reported at $8,473. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.
Show as a table
| Year | Mark Blecher | Ophthalmology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $133,835 | $258 | $104–$655 | $163 |
| 2020 | $69,455 | $126 | $45–$321 | $114 |
| 2021 | $57,304 | $205 | $76–$534 | $132 |
| 2022 | $36,824 | $266 | $100–$678 | $149 |
| 2023 | $34,417 | $308 | $117–$745 | $160 |
| 2024 | $16,998 | $340 | $127–$846 | $164 |
| 2025 | $8,473 | $384 | $136–$917 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$12,601
Medicare patients
38
Services billed
79
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 47% | |
| Diabetes | 37% | |
| Chronic kidney disease | 34% | |
| Ischemic heart disease | 32% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
220 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Ophthalmology in Pennsylvania
Related records
Ophthalmology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Ophthalmology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.